Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors

Haemophilia

Volumn 15, Issue 4, 2009, Pages 904-910

  Martinowitz, U ^a   Livnat, T ^a,b   Zivelin, A ^a,b   Kenet, Gili ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

FEIBA; Haemophilia; Inhibitors; rFVIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TREATMENT FAILURE; EX VIVO STUDY; FIBRINOGEN BLOOD LEVEL; HEMARTHROSIS; HEMATURIA; HEMOPHILIA A; HEMOSTASIS; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MUSCLE BLEEDING; MUSCLE HEMATOMA; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTE POOR PLASMA; THROMBOEMBOLISM; THROMBOSIS;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FACTOR VIIA; HEMARTHROSIS; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RECOMBINANT PROTEINS; THROMBIN; YOUNG ADULT;

EID: 67649868161     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02028.x     Document Type: Article

References (30)

1. Santagostino E, Mancuso ME, Rocino A et.al. Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study. Br J Haematol 2005; 130: 422-7.
2. White GC II, Kempton CL, Grimsley A, Nielsen B, Roberts HR. Cellular immune responses in hemophilia: Why do inhibitors develop in some, but not all hemophiliacs? J Thromb Haemost 2005; 3: 1676-81.
3. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26: 179-88.
4. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: A multicenter therapeutic trial. N Engl J Med 1980; 303: 421-5.
5. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP et.al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305: 717-21.
6. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomized comparison. Haemophilia 2008; 14: 287-94.
7. Key NS, Aledort LM, Beardsley D et.al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-20.
8. Kavakli K, Markis M, Zulficar B, Erhadrdsen E, Abrams ZS, Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
9. Santagostino E, Manusco ME, Rosino A, Manusco G, Scraggi F, Mannuci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
10. Hayashi T, Tanaka I, Shima M et.al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004; 10: 397-400.
11. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 2004; 10: 347-51.
12. Martinowitz U, Livnat T, Zivelin A, Seligsohn U, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in severe hemophilia A patients with an inhibitor to factor VIII who are refractory to rFVIIa or FEIBA has an excellent hemostatic effect and synergistically enhances thrombin generation. J Thromb Haemost 2005; 3: Abstract PO637.
13. Dargaud Y, Beguin S, Lienhart A et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
14. Parmer N, Berry LR, Paredas N, Chan AK. Effect of heparins on thrombin generation in hemophilic plasma supplemented with FVIII, FVIIa, or FEIBA. Clin Lab 2005; 51: 157-66.
15. Livnat T, Martinowitz U, Zivelin A, Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia 2008; 4: 782-6.
16. Váradi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
17. Livnat T, Zivelin A, Martinowitz U, Salomon O, Seligsohn U. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. J Thromb Haemost 2006; 4: 192-200.
18. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus mega-dose of recombinant activated Factor VII (NovoSeven®). J Thromb Haemost 2003; 1: 450-455.
19. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: Update of our previous experience. Haemophilia 2007; 13: 244-8.
20. Kraut EH, Aledort EM, Arkin S, Stines KC, Wong WY. Surgical interventions in a cohort of patients with hemophilia A and inhibitors: an experimental retrospective chart. Haemophilia 2007; 13: 508-17.
21. Teitel J, Berntrop E, Collins P et.al. A systematic approach to controlling problem bleeds in patients with severe congenital hemophilia patients and high-titre inhibitors. Haemophilia 2007; 13: 56-63.
22. Monroe DM. Further understanding of recombinant activated factor VII mode of action. Semin Hematol 2008; 45(2 Suppl 1): S7-11.
23. Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 2002; 88: 60-5.
24. Allen GA, Hoffman M, Roberts H, Monroe DM. Manipulation of protrombin concentration improves response to high dose factor VIIa in a cell-based model of hemophilia. Br J Hematol 2006; 134: 314-9.
25. Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J. The economic impact of FVIII inhibitors in patients with hemophilia. Haemophilia 2004; 10: 63-8.
26. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypassing activity. J Thromb Haemost 2004; 2: 1700-8.
27. Karayalcin G, Goldberg B, Cherrick I et.al. Acute myocardial infarction complicating prothrombin concentrate therapy in an 8year old boy with hemophilia A and factor VIII inhibitor. Am J Hematol Oncol 1993; 15: 416-9.
28. Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
29. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008; 14: 898-902.
30. Rosenfeld SB, Watkinson KK, Thompson BH, Macfarlane DE, Lentz SR. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient. Thromb Haemost 2002; 87: 925-6.